Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H15ClO4 |
Molecular Weight | 318.752 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2)C(O)=O
InChI
InChIKey=MQOBSOSZFYZQOK-UHFFFAOYSA-N
InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)
Molecular Formula | C17H15ClO4 |
Molecular Weight | 318.752 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL239 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17343371 |
4500.0 nM [EC50] | ||
Target ID: CHEMBL4879 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18533710 |
1000.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FIBRICOR Approved UseFIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator
indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe
hypertriglyceridemia (> 500 mg/dL); to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. Launch Date2009 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 μg/mL |
105 mg 1 times / day single, oral dose: 105 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOFIBRIC ACID plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
8.37 μg/mL |
105 mg 1 times / day single, oral dose: 105 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOFIBRIC ACID plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
162.96 μg × h/mL |
105 mg 1 times / day single, oral dose: 105 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOFIBRIC ACID plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
124.89 μg × h/mL |
105 mg 1 times / day single, oral dose: 105 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOFIBRIC ACID plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
105 mg 1 times / day steady-state, oral dose: 105 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FENOFIBRIC ACID serum | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Constipation, Diarrhea... Other AEs: Constipation (3.3%) Sources: Diarrhea (3.9%) Dyspepsia (3.7%) Nausea (4.3%) Fatigue (2%) Pain (3.5%) Nasopharyngitis (3.5%) Sinusitis (3.3%) Upper respiratory tract infection (5.3%) ALT increased (1.2%) Arthralgia (3.9%) Back pain (6.3%) Muscle spasms (1.6%) Myalgia (3.3%) Pain in extremity (4.5%) Dizziness (4.1%) Headache (12.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
ALT increased | 1.2% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Muscle spasms | 1.6% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Headache | 12.7% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Fatigue | 2% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Constipation | 3.3% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Myalgia | 3.3% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Sinusitis | 3.3% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Nasopharyngitis | 3.5% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Pain | 3.5% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Dyspepsia | 3.7% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Arthralgia | 3.9% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Diarrhea | 3.9% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Dizziness | 4.1% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Nausea | 4.3% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Pain in extremity | 4.5% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Upper respiratory tract infection | 5.3% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Back pain | 6.3% | 135 mg 1 times / day multiple, oral Recommended Dose: 135 mg, 1 times / day Route: oral Route: multiple Dose: 135 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
OverviewOther
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
minor | ||||
minor | ||||
minor | ||||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no |
PubMed
Title | Date | PubMed |
---|---|---|
PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells. | 2001 Aug 24 |
|
Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. | 2001 Aug 24 |
|
A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. | 2001 Feb |
|
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. | 2001 Jun |
|
Comparison of DNA damage photoinduced by ketoprofen, fenofibric acid and benzophenone via electron and energy transfer. | 2001 Nov |
|
Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid. | 2002 May 1 |
|
Update on fenofibrate. | 2002 Winter |
|
A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor. | 2003 Jan 24 |
|
Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. | 2004 |
|
A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. | 2004 Sep |
|
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. | 2005 Feb |
|
Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors. | 2005 Sep 2 |
|
Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. | 2007 |
|
Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. | 2007 Aug |
|
PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. | 2008 Aug 15 |
|
An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection. | 2008 May 2 |
|
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. | 2009 |
|
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. | 2009 |
|
Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs. | 2009 |
|
Advances in the medical treatment of diabetic retinopathy. | 2009 Aug |
|
Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier. | 2009 Aug |
|
Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature. | 2009 Dec |
|
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. | 2009 Feb 15 |
|
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. | 2009 Jan |
|
Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine. | 2009 Jun |
|
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. | 2009 May |
|
Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels. | 2009 Nov |
|
In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. | 2009 Nov |
|
Myopathy with statin-fibrate combination therapy: clinical considerations. | 2009 Sep |
|
Medicinal chemistry of drugs used in diabetic cardiomyopathy. | 2010 |
|
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. | 2010 |
|
Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain. | 2010 Apr |
|
Occurrence of emerging pollutants in urban wastewater and their removal through biological treatment followed by ozonation. | 2010 Jan |
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:31:26 GMT 2025
by
admin
on
Mon Mar 31 18:31:26 GMT 2025
|
Record UNII |
BGF9MN2HU1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175596
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
||
|
NCI_THESAURUS |
C98150
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
24852
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | RxNorm | ||
|
BGF9MN2HU1
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
DTXSID8041030
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
64929
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
SUB34521
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
281318
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
42017-89-0
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
Fenofibric acid
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
1269436
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
83469
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
100000128002
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
BGF9MN2HU1
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
m5279
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
1269618
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
ALTERNATIVE | |||
|
CHEMBL981
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
C83804
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
C006012
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
DB13873
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY | |||
|
255-626-9
Created by
admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> AGONIST |
|
||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
MAJOR
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|